To summarize recommendations for the use of intravitreal aflibercept with a treat-and-extend regimen to manage neovascular age-related macular degeneration (nAMD) in the Asia-Pacific region. Although anti-vascular endothelial growth factor therapies have improved the quality of life of patients with nAMD, a leading cause of blindness and visual impairment, the high treatment frequency recommended by current guidelines places a significant burden on patients and healthcare providers. Results: After 3 initial monthly doses, treatment interval could be extended by 4-week increments, to a maximum of 12 weeks, in patients with inactive disease. Conversely, in active disease, treatment intervals should be shortened, by 4 weeks, or to 4 weeks in cases of severe recurrence. Treatment could be ceased in patients with stable disease activity after 12 months of treatment at 12-week intervals, as a means to prevent over treatment and lifelong injections.
Asian and white populations share key risk factors for nAMD, including age, cigarette smoking, obesity, sunlight exposure, and cardiovascular disease.
9,10 However, the manifestation of the condition may be quite different. Thus, it is important to consider the epidemiology, genetic factors, phenotypic presentation, and clinical subtypes of nAMD in the Asian population from a unique perspective.
Moreover, social factors affect the determinants of successful treatment and must be considered in any management recommendations. Despite the clear burden of poorly managed nAMD, the majority of patients living in the Asia-Pacific region are not receiving the optimal evidence-based care needed to prevent severe visual loss. This is mainly due to the following: (a) lack of awareness about the importance of early diagnosis and treatment, (b) limited access to diagnostic screening and treatment, (c) high financial costs of anti-vascular endothelial growth factor (anti-VEGF) treatments and relative lack of reimbursement, (d) fragmented delivery-of-care systems, and (e) limited access to continuing care (patient follow-up).
Pathophysiology of Neovascular AMD
The underlying etiology of nAMD is complex and its direct cause is not fully understood. What is known is that overexpression of VEGF leads to choroidal neovascularization (CNV). The new blood vessels tend to be disorganized and more permeable than their normal counterparts; thus, blood and fluid leak into the macula. Over time, this leakage results in the characteristic clinical features of nAMD: increased retinal thickness, subretinal fluid accumulation, intra-or subretinal hemorrhage, retinal pigment epithelial (RPE) detachment, and/or sub-RPE hemorrhage.
Other growth factors may contribute to CNV but their roles are only just starting to be elucidated. Placental growth factor (PlGF), a member of the VEGF family, is one such molecule. Upregulation of PlGF has been observed in human nAMD and mouse models of laser-induced CNV, 11, 12 suggesting that it might 13 Additionally, PlGF has been implicated in the pathogenesis of diabetic retinopathy by modulating hyperpermeability of RPE cells, ultimately leading to subretinal fluid accumulation and edema. 8 The potential role of PlGF on the pathogenesis of diabetic retinopathy is supported by the observation that high levels of PlGF are found in the vitreous of patients with diabetic retinopathy.
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Treatment Options for Neovascular AMD
The primary goals for the treatment of nAMD are improvement in visual acuity (VA), reduction of fluid and blood leakage, and complete regression of choroidal neovascularization. Treatment options have included laser photocoagulation, photodynamic therapy, steroids, and anti-VEGF agents.
The introduction of intravitreal anti-VEGF agents within the past decade has revolutionized the treatment of nAMD, offering patients improvements in vision previously unachievable. A number of anti-VEGF agents are available to treat nAMD, with aflibercept, ranibizumab, and bevacizumab being most commonly used. Aflibercept and ranibizumab are licensed for use in nAMD, but bevacizumab, originally developed for use in an oncology setting, is not approved for ocular use. The decision of which agent to use will be driven by physician choice and influenced by factors such as availability and access, along with reimbursement considerations.
Ranibizumab, a humanized monoclonal antibody fragment, was the first anti-VEGF agent shown to improve VA in patients with nAMD.
15-17 Regulatory approval for the monthly 0.5 mg dose was granted on the basis of the MARINA 16, 18, 19 and ANCHOR 15,20 study data, which showed mean gains of 7-11 letters over 12 months.
The newest agent, aflibercept, is a fusion protein 21,22 capable of binding strongly to VEGF-A with 1:1 stoichiometry 1,21 and also to PlGF. The licence for intravitreal aflibercept injections (IVT-AFL) was granted based on the VIEW 1 and VIEW 2 23 studies, which demonstrated equivalent efficacy to ranibizumab, with a less frequent dosing schedule (8-weekly, after 3 initial monthly doses).
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The duration of the biological activity of individual anti-VEGF agents may be different and may influence their suitability for different treatment regimens. Studies demonstrate a mean duration of intraocular VEGF suppression of 70.5 days with IVT-AFL, 24 offering the potential for extended treatment intervals.
Management of Neovascular AMD with Anti-VEGF Agents: Reactive versus Proactive Regimens
Fixed proactive treatment regimens (eg, monthly injections) have been shown to have great potential to improve and maintain VA. 15, 16, 23, [25] [26] [27] However, adherence to monthly treatment regimens may be difficult to maintain, especially in self-pay markets such as Asia-Pacific countries where the high costs of anti-VEGF agents, such as IVT-AFL and ranibizumab, may be a significant financial burden for patients. Moreover, monthly visits are unrealistic for most patients, who often rely on their family members to bring them to the clinic. Additionally, any intraocular anti-VEGF injection carries a potential risk of ocular (eg, inflammation, increased intraocular pressure, and endophthalmitis) and theoretical systemic (eg, cardiovascular) side effects.
28,29 For these reasons, 2 alternative treatment strategies-pro re nata (PRN; as needed) and treat-and-extend-have been trialled in an attempt to reduce treatment burden.
PRN as a Reactive Approach
The PRN regimen has been extensively used in the clinic as a means of minimizing injection frequency while aiming to maintain the best possible visual outcomes. [25] [26] [27] 30, 31 In principle, a PRN regimen involves frequent (monthly) monitoring, with treatment given only when patients show symptomatic disease.
In studies of ranibizumab for the treatment of nAMD, reducing injection frequency by using PRN treatment regimens has led to variable outcomes, with mean VA gains of 2.3-11.1 letters. [25] [26] [27] 30, [32] [33] [34] In the HARBOR 25,32 study, which evaluated the efficacy of ranibizumab with a monthly or PRN regimen (with strict monitoring criteria), visual outcomes of the PRN arms were similar to the monthly arms of the study and to those seen in pivotal clinical trials (MARINA, ANCHOR)
15,16,18-20 that followed a monthly treatment schedule.
Additionally, 1-year results from the CATT study 26 show that a ranibizumab PRN regimen, following strict monitoring and retreatment criteria, was equivalent to a monthly regimen, with patients gaining a mean of 8.5 and 6.8 letters, respectively. Similarly, the IVAN study demonstrated similar visual outcomes between a monthly and PRN dosing regimen (mean gains of 5.5 and 3.5 letters, respectively) 35, 36 ; however, the PRN regimen used was atypical, in that patients requiring retreatment were given a new initial cycle consisting of 3 monthly injections (overall average of 18 treatments in 2 years). 35, 36 In the SAILOR 33 study, which used a PRN regimen based on quarterly monitoring visits after 3 initial doses, there was a mean gain of only 2.3 letters. Moreover, improvements in visual and anatomical outcomes achieved during an initial monthly treatment period (typically 3 monthly doses) often decline when patients transition to a PRN regimen. 31, 33, 37 Taken together, the results from these studies suggest that only PRN regimens with frequent monitoring and strict retreatment criteria can achieve the visual outcomes similar to those seen with monthly dosing.
As-needed regimens are even less likely to be effective in normal clinical practice, where the monitoring requirements and retreatment criteria used are nearly always less stringent than in a clinical trial setting. Indeed, there is growing evidence that in "real life" patients are typically not monitored monthly and correspondingly VA outcomes are poor, with a loss of 1-3.2 letters after 4.3-5.1 injections at 12 months.
38-41
Several factors contribute to suboptimal PRN monitoring frequency in the clinic. In the first instance, there is generalized confusion and lack of clarity about the regimen itself and therefore some clinics do not mandate monthly visits. Furthermore, in clinics that do schedule monthly visits, adherence can be problematic because patients do not see the value of visiting every month when they only receive treatment on some occasions. Additionally, poor adherence to retreatment criteria and delays between treatment schedule and administration can also contribute to the poor visual outcomes associated with PRN.
Treat-and-Extend as a Proactive Approach
Recently, the proactive treat-and-extend regimen has emerged as a practical and effective alternative method of reducing the treatment burden without negatively affecting visual and anatomical outcomes. With treat-and-extend, the patient receives treatment at every visit; however, the interval between visits is gradually increased once stabilization of the disease is achieved.
A nAMD retrospective study by Oubraham et al 42 compared the efficacy of anti-VEGF therapy (ranibizumab) administered via either a treat-and-extend or PRN regimen. Visual acuity gains at 12 months were higher in the treat-and-extend arm compared with the PRN arm (10.8 versus 2.3 letters, respectively), with patients in the former receiving a mean of 7.8 versus 5.2 injections.
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Switching from a PRN to a treat-and-extend regimen has also been shown to improve VA (by a mean of 3 letters) while reducing the number of clinic visits, albeit with a greater number of injections (0.76 vs. 0.47 per month). 43 In addition, a comparative case series of treatment-naive patients reinforced the idea that a treat-and-extend regimen is often associated with improved visual outcomes when compared with a PRN regimen. 44 In this study, patients switching from a PRN to a treat-and-extend regimen saw an increase in visual acuity from 0.49, during the PRN maintenance phase (mean duration of 17 months), to 0.55 and 0.56 at 6 and 12 months, respectively.
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Results from the LUCAS 45 study showed good outcomes (52 weeks) for treat-and-extend in the management of nAMD, with patients gaining a mean of 8.2 letters over 8 treatments with ranibizumab. 45 Similar visual gains (a 10-11 and 8-11 letter gain from baseline at 12 and 24 months, respectively) were reported in the ATLAS 46 study, in which IVT-AFL was administered following a treat-and-extend regimen in patients with nAMD, with a mean of 13.9 injections given over the course of 2 years (mean of 8 injections at 12 months and an additional 5.9 by the end of month 24). 46 Other evaluations of the treat-and-extend approach as an alternative to PRN and fixed regimens have reported variable outcomes, with mean 12-month gains in VA ranging from 3 to 16.2 letters, 47-52 with a mean number of 8-9 injections. 47-51 The variability in outcomes seen in these studies could be attributed to a number of factors, including differences in the anti-VEGF drugs used (ranibizumab, bevacizumab) and baseline VAs. Moreover, different interpretations of the treat-and-extend regimen could have influenced the results and highlight the need for guidance on implementation of such an approach. Nevertheless, the results of these studies confirm the potential for treat-and-extend to provide the visual benefits achieved by fixed monthly dosing in pivotal clinical trials. More recently, a study (n = 85) in patients with nAMD treated with aflibercept according to the label (fixed bimonthly regimen for the first 12 months after 3 initial monthly injections, followed by treat-and-extend), reported a gain of 7.2 and 8.7 at month 12 and month 18, respectively.
53 These improvements were associated with a corresponding improvement in the median near VA at 12 months-12 points at baseline to 5 points at 12 months-a result that was maintained at month 18.
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In the next section, we propose guidelines for the implementation of a treat-and-extend regimen using IVT-AFL in the AsiaPacific region to optimize visual outcomes and minimize burden in nAMD. The scope of these guidelines is limited to the application of IVT-AFL in the treatment of nAMD and does not include recommendations for other commonly used anti-VEGF agents.
MATERiAls AND METhODs
An expert panel comprising the authors and 3 additional international medical retina specialists met in Tokyo, Japan, to discuss the application of IVT-AFL in the treatment of nAMD in the Asia-Pacific region. The following regions and countries were represented: Hong Kong, Indonesia, Korea, Malaysia, Singapore, and Taiwan.
The main aim of the meeting was to evaluate current clinical practice and consider how a treat-and-extend approach could be implemented to facilitate optimal outcomes. A consensus algorithm for the use of IVT-AFL with a treat-and-extend approach is presented below. It should be noted that the licensed posology for IVT-AFL is stated in months. However, as most clinics are set up using weekly rather than monthly schedules, the dosing guidelines provided in this manuscript are given in weeks rather than in months. For example, "8-weekly" (q8) dosing is considered to be equivalent to "every other month" dosing.
REsulTs initiation of Treatment
Treatment should start with 3 mandatory 4-weekly (q4) injections followed by extension to a q8 interval.
This initial dose schedule is simple, predictable, and familiar to both physicians and patients, as it is used routinely in the clinic. As the initial response to anti-VEGF is exponential, it is important to prime patients with sufficient IVT-AFL to bring the disease under control as quickly as possible to optimize visual gains. Results from clinical trials support the use of 3 initial doses. Currently, there is no evidence that supports omitting the 3 initial doses and adopting a treat-and-extend regimen from the outset.
Extension
After the initial period (3 monthly injections with IVT-AFL), patients meeting the extension criteria can have their treatment interval extended by 4 weeks at a time, with a maximum treatment interval of 12 weeks in patients with inactive disease.
The goal of the extension period is to find the optimal treatment interval at which there is maximum control of disease activity and stabilization of VA with minimum treatment burden.
Current treat-and-extend regimens extend the treatment interval by 2 weeks; however, as the VIEW studies showed that patients who received q8 treatment in year 1 (after 3 initial monthly doses) had similar visual outcomes to those treated monthly, an immediate extension to 8 weekly dosing seems reasonable. 25 Although there are no data to support treat-and-extend per se, the VIEW 1 study provided robust data on a modified quarterly dosing (minimum dosing every 12 weeks with interim as needed monthly injections) supporting extension to 12-week intervals in year 2 (91-92% of patients maintained visual gains at the end of year 2). Therefore, it may be possible to extend the treatment interval up to this point on an individual basis. Additionally, studies of intraocular VEGF suppression show a mean duration of VEGF suppression of 70.5 days with IVT-AFL, 24 thus facilitating extended treatment intervals.
Extending the treatment interval in 4-week increments has advantages for patients (in terms of treatment costs) and the clinic (in terms of scheduling visits) compared with the alternative 2 weekly increments used by existing treat-and-extend regimens.
For a patient responding well and having their treatment interval extended at the earliest opportunity, the recommended treatment approach would result in the following injection schedule (weeks): 0-4-8-16-24-36-48, with 7 mandatory injections in total given in the first year of treatment (Fig. 1) . This number of treatments is consistent with most PRN studies showing acceptable visual outcomes at year 1 and should not be deemed excessively high.
Assessment Criteria
Criteria for extending treatment should be easy to follow and be based on the absence of disease activity, as indicated by stable vision, a dry retina, or stable retinal thickness.
As a general rule, vision is considered stable in the absence of a change of at least 5 letters between 2 consecutive visual acuity measurements. Additionally, retinal thickness is considered stable if there is less than a 50 µm increase from the thinnest macular measurement on optical coherence tomography.
Persistent subretinal or intraretinal fluid should not be tolerated. Existing treatment intervals should be maintained if persistent fluid is present.
Some level of physician discretion is required to differentiate intraretinal cysts from other types of fluid, as intraretinal cysts may not necessarily indicate activity but may result from cystoid degenerative changes.
With regard to retinal pigment epithelium detachment, the lesion may be considered stable if no change has been demonstrated on 2 consecutive visits.
Provided these criteria are met, the treatment interval may be extended.
The presence of hard exudates and lipids, along with subjective symptoms such as visual distortion, should not be included as assessment criteria because they are considered too variable and subjective in the monitoring of nAMD patients. 
Reduction of Treatment interval
If criteria for extension of the treatment interval are not met, the treatment interval should be reduced by 4 weeks. The treatment interval should be reduced by 4 weeks if there is new hemorrhage or loss of visual acuity (≥5 letter drop).
In practical terms, if a patient has stable disease with q8 but not 12-weekly (q12) treatment, the treatment interval should be initially reduced to q8. If the disease remains unstable, the treatment interval should be further reduced to q4.
In the case of a severe recurrence of disease activity, an instant reduction to q4 intervals should be allowed as a rescue scenario, even if the patient was previously being managed with q12 treatment. A severe recurrence is defined as a significant loss of VA (≥15 letters), a massive hemorrhage, or significant RPE detachment.
stopping Treatment
Because nAMD is thought to be chronic and progressive, treatment may be required indefinitely. However, it is reasonable to attempt to stop treatment in patients with inactive disease who have completed at least 12 months of treatment given at 12-week intervals. The allowance to stop treatment in patients with stable disease provides a mechanism by which over-treatment and lifelong injections for the patient can be avoided. Once treatment is stopped, these patients should be monitored closely for recurrences.
Stopping treatment after 72 weeks with appropriate followup (eg, quarterly monitoring) until the end of year 2 could be acceptable and would present minimal risk. The best-case scenario in a patient with an optimal response would result in a total of 7 injections given in the first year of treatment and 4 injections in the second year (Fig. 1) .
Further Considerations
Additional studies are necessary to address the validity of treat-and-extend for the management of polypoidal choroidal vasculopathy (PCV) and retinal angiomatous proliferation (RAP) lesions. Treat-and-extend, with or without photodynamic therapy, could be a useful regimen for managing sudden massive hemorrhages, which are a common feature in patients with PCV. However, the approach to the treatment of RAP lesions is challenging. The high risk of recurrence in patients with RAP might suggest that a proactive treatment strategy could be favored over a reactive regimen. Nevertheless, a proactive strategy could be associated with more frequent injections compared with a reactive regimen. Additionally, it is thought that more frequent injections could potentially increase the risk of development of geographic atrophy in patients with RAP. Further analyses are required to clearly define the appropriate treatment regimen for patients with RAP.
DisCussiON
These guidelines provide a suggested treat-and-extend protocol for use with IVT-AFL only. As previously indicated, other anti-VEGF agents are in use in clinical practice across the AsiaPacific region; however, the specifics of a recommended treatment protocol with these agents will be different to that outlined here.
Current anti-VEGF management of nAMD in the AsiaPacific region relies on a fixed regimen in year 1, with the possibility of extending treatment in year 2. The majority of patients in these self-pay markets are not receiving optimal eye care because of poor treatment adherence and the high financial costs of anti-VEGF treatment. 54 A lack of disease understanding by the public and policy makers, and limited access to diagnostic screening and patient follow up, add to the problem.
Implementation of a proactive treat-and-extend regimen using IVT-AFL may help to address these issues by minimizing the total number of clinic visits and injections per year, while preventing under-treatment by guaranteeing a minimum number of injections (Table 1) . Therefore, we propose that such a regimen should be considered as a suitable proactive treatment approach for the management of nAMD. The main disadvantage of treat-andextend is the difficulty of integrating it into clinical practice because it relies on the ability of hospitals to schedule flexible appointments and to avoid confusion when scheduling visits (Table 1) .
For this reason, we propose straightforward IVT-AFL treatand-extend guidelines that should be tested in a clinical setting. A number of studies are planned or underway to assess the use of 
Treat-and-Extend
IVT-AFL treat-and-extend regimens in patients with nAMD. 55, 56 Further discussion and studies are necessary to assess the validity of a treat-and-extend regimen for nAMD clinical subtypes that respond differently to anti-VEGF agents.
